NCT01413711撤回4 期
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 发起方
- Lundbeck LLC
- 主要终点
- Non-compartmental pharmacokinetic profile of vigabatrin after oral administrations in infants(>=1 and <6 months of age)
研究概览
简要总结
The primary objective of the study is to evaluate vigabatrin pharmacokinetics (PK) in neonates receiving vigabatrin for infantile spasms (IS); and to determine the safety of vigabatrin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 1 Month 至 6 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient's parent or legally authorized representative is able to read and understand the Patient Information Sheet and Informed Consent Form.
- •The patient's legally authorized representative has signed the Informed Consent Form.
- •The patient has IS, diagnosed according to the International League Against Epilepsy (ILAE) criteria.
- •The patient is a full term (38 weeks gestation) male or female, aged >=1 month to <6 months at the time of enrollment.
- •The patient's length and body weight for gestational age is >=5th and <=95th percentile, according to Centers for Disease Control and Prevention (CDC) Growth Charts.
排除标准
- •The patient is currently being treated or has been previously treated with vigabatrin.
- •The patient is a member of the site personnel's immediate family.
- •The patient takes or has taken disallowed recent or concomitant medication or it is anticipated that the patient will require treatment with at least one of the disallowed concomitant medications during the study.
- •The patient has a history of severe drug allergy or hypersensitivity, or known hypersensitivity to the investigational medicinal product (IMP) or the excipients (povodone/iodine) of the IMP.
- •The patient has any other disorder for which the treatment takes priority over treatment of IS or is likely to interfere with study treatment or impair treatment compliance.
- •The patient has been treated with any IMP within 30 days or 5 half lives (whichever is longer) prior to the Screening Visit.
- •The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
- •The patient has been diagnosed or is judged by the investigator to have anemia.
- •The patient has been diagnosed or is judged by the investigator to have renal insufficiency.
- •The patient's parent or legally authorized representative is, in the investigator's opinion, unlikely or unwilling to comply with the protocol or the patient is unsuitable for any reason.
研究组 & 干预措施
Vigabatrin
Experimental
干预措施: Vigabatrin (Drug)
结局指标
主要结局
Non-compartmental pharmacokinetic profile of vigabatrin after oral administrations in infants(>=1 and <6 months of age)
时间窗: 24 hrs post dose on Day 1 and 12 hrs post dose on Day 5
Serial blood for plasma generation will be collected on Days 1 and 5 and vigabatrin concenrations determined to the determine the pharmacokinetic profile of vigabatrin
次要结局
- To determine the safety of vigabatrin following oral dose administrations in infants (>=1 and <6 months of age)(Safety collected throughout the 5-day study)
研究者
相似试验
已完成
不适用
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial EpilepsyInfantile SpasmsNCT02220114Orphelia Pharma38
终止
1 期
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)Gram-Positive Bacterial InfectionsNCT02013141Cumberland Pharmaceuticals22
招募中
2 期
A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CICNeurogenic Detrusor OveractivityNCT05491525Urovant Sciences GmbH85
已完成
1 期
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)Overactive BladderNCT01737684Merck Sharp & Dohme LLC16
终止
3 期
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic SeizuresElectroencephalographic Neonatal SeizuresNCT03325439UCB Biopharma SRL9